Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials

// Helen J. MacKay 1 , Douglas A. Levine 2 , Victoria L. Bae-Jump 3 , Daphne W. Bell 4 , Jessica N. McAlpine 5 , Alessandro Santin 6 , Gini F. Fleming 7 , David G. Mutch 8 , Kenneth P. Nephew 9 , Nicolas Wentzensen 10 , Paul J. Goodfellow 11 , Oliver Dorigo 12 , Hans W. Nijman 13 , Russell Broaddus 14 and Elise C. Kohn 15 1 Division of Medical Oncology & Hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada 2 Division of Gynecologic Cancer, Department of OB/GYN, NYU Langone Laura and Isaac Perlmutter Cancer Center, New York, NY, United States 3 Division of Gynecologic Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, CA, United States 4 Reproductive Cancer Genetics Section, Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute/NIH, MSC 8000, Bethesda, ML, United States 5 University of British Columbia & BC Cancer Agency, Division of Gynecologic Oncology, Vancouver, British Columbia, Canada 6 Department of Gynecology, Obstetrics and Reproductive Sciences, Yale School of Medicine, New Haven, CT, United States 7 Section of Hematology-Oncology, Department of Medicine, The University of Chicago, Chicago, IL, United States 8 Department of Obstetrics & Gynecology, Washington University School of Medicine, St. Louis, MO, United States 9 Medical Sciences Program, Indiana University School of Medicine, Bloomington, IN, United States 10 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, ML, United States 11 James Comprehensive Cancer Center and The Department of Obstetrics and Gynecology, Ohio State University, Columbus, OH, United States 12 Division Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford, CA, United States 13 Department of Gynecology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands 14 Department of Pathology, Unit 85, University of Texas M.D. Anderson Cancer Center, Houston, TX, United States 15 Clinical Investigations Branch of The Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, ML, United States Correspondence to: Elise C. Kohn, email: kohne@mail.nih.gov Keywords: endometrial cancer, molecular targets Received: March 03, 2017 Accepted: May 15, 2017 Published: August 03, 2017 ABSTRACT The incidence and mortality rates from endometrial cancer are increasing. There have been no new drugs approved for the treatment of endometrial cancer in decades. The National Cancer Institute, Gynecologic Cancer Steering Committee identified the integration of molecular and/or histologic stratification into endometrial cancer management as a top strategic priority. Based on this, they convened a group of experts to review the molecular data in this disease. Here we report on the actionable opportunities and therapeutic directions identified for incorporation into future clinical trials.